James A. Datin became a member of the Board in August 2019 and serves on the Audit Committee and as chair of the Compensation Committee. From November 2013 to June 2022, Mr. Datin served as President and CEO of BioAgilytix Labs, LLC, a leading global bioanalytical contract research organization, and as a member of its board of directors until December 2022. From September 2005 to July 2013, Mr. Datin served as Executive Vice President and Managing Director at Safeguard Scientifics, Inc., a company focused on providing capital and advice to technology driven businesses in healthcare, financial services and digital media. Prior to that time, Mr. Datin served as CEO of Touchpoint Solutions, Inc., a remote management and monitoring company serving the medical, imaging, print, retail and other industries. He has also held senior leadership positions at Dendrite International, Inc., GlaxoSmithKline PLC, the Isuta Holdings Group of companies, Baxter and other companies. Mr. Datin has served on the Advisory Board of Marshall University School of Business since 2013 and on the board of North Carolina Biotechnology Center as a member since 2017. He previously served on the boards of directors of FSD Pharma Inc., Life Sciences Pennsylvania and NovaSom, Inc. Mr. Datin received a B.B.A. at Marshall University, an M.B.A. at the University of New Haven and an Advanced Management Degree at The Wharton School at The University of Pennsylvania.